Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Dr. med. Diamant Thaçi
University of Lübeck, Lübeck, Germany
Prof. Dr. med. Diamant Thaçi is a director and full university professor at the Institute for Inflammation Medicine and Comprehensive Center for Inflammation Medicine at the University of Lübeck, Germany, a position he has held since 2013. He is chairman of the inflammatory board at the University Hospital Schleswig-Holstein, Campus Lübeck. read more
His research experience includes basic immunology and all stages of clinical drug development, especially in chronic inflammatory skin diseases such as atopic dermatitis, hidradenitis suppurativa and psoriasis. He has been involved in numerous investigator-driven trials, and acted as main investigator on many national and international multicentre trials. In addition to his clinical commitments, Prof. Dr. Thaçi is a lecturer in dermatology and cross-section immunology/microbiology.
Prof. Dr. Thaçi is a steering committee member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), and an active member of the International Psoriasis Council (IPC), International Eczema council (IEC) and Skin Inflammation & Psoriasis International Network (SPIN). He has been a recipient of the Theodor-Stern Foundation Award for excellent clinical research.   Â
Prof. Dr. Thaçi has authored numerous articles in high-tier journals such as the New England Journal of Medicine and The Lancet and is the editor, co-editor and editorial board member of several journals. He also serves as a scientific reviewer for dermatological and general medicine journals.
Prof. Dr. med. Diamant Thaçi discloses Advisory board/panel fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Leo Pharma, Novartis, Pfizer and UCB. Consultancy fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Leo Pharma, Novartis, Pfizer and UCB. Grants/research support from AbbVie, Leo and Novartis. Speaker’s bureau fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Roche-Posay, Sanofi and UCB.
Dr Benjamin Ungar
Icahn School of Medicine at Mount Sinai, New York, NY, USA
Dr Benjamin Ungar is an assistant professor in the Department of Dermatology at Icahn School of Medicine at Mount Sinai, New York, USA and in 2023 became the Director of the Alopecia Center of Excellence at Mount Sinai. read more
Dr Ungar graduated from Harvard University cum laude in 2009 and began medical school at the Icahn School of Medicine in 2011. From 2014 to 2016, he completed a research fellowship in the Laboratory for Investigative Dermatology at Rockefeller University, after which he graduated from Medical School in 2017 with distinction in research.Â
After completing his intern year at NYU Winthrop Hospital, Dr Ungar began his dermatology residency at Mount Sinai, from which he graduated as the Chief Resident in June 2021. During the last year of his residency, Dr Ungar completed a T32 NIH Research Training Fellowship.
Dr Benjamin Ungar discloses Advisory board/panel fees from Arcutis Biotherapeutics, Bristol Myers Squibb, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi and UCB. Grants/research support from Bristol Myers Squibb, Incyte, Pfizer, Rapt Therapeutics and Sanofi.
